Pitcairn Co. Has $1.30 Million Stake in Pfizer Inc. $PFE

Pitcairn Co. boosted its holdings in Pfizer Inc. (NYSE:PFE) by 70.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 53,814 shares of the biopharmaceutical company’s stock after buying an additional 22,158 shares during the period. Pitcairn Co.’s holdings in Pfizer were worth $1,304,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the period. Vestmark Advisory Solutions Inc. bought a new position in Pfizer during the 1st quarter worth approximately $474,000. Forvis Mazars Wealth Advisors LLC grew its holdings in Pfizer by 4.0% during the first quarter. Forvis Mazars Wealth Advisors LLC now owns 52,489 shares of the biopharmaceutical company’s stock valued at $1,330,000 after purchasing an additional 1,996 shares during the period. Finally, Alliance Wealth Advisors LLC UT increased its stake in Pfizer by 21.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 15,270 shares of the biopharmaceutical company’s stock valued at $387,000 after purchasing an additional 2,699 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on PFE. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Citigroup began coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target for the company. Morgan Stanley dropped their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.33.

Pfizer Stock Performance

PFE opened at $25.86 on Monday. The company has a market capitalization of $147.04 billion, a price-to-earnings ratio of 15.04 and a beta of 0.46. The business’s 50-day moving average price is $25.12 and its two-hundred day moving average price is $24.78. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.